Bioavailability Study of Amlodipine Besylate/Atorvastatin Calcium Tablets 10/80 mg Under Fed Condition

Dr.Reddy's Laboratories

Status and phase

Completed

Phase 1

Conditions

Healthy

Treatments

Drug: Amlodipine besylate/Atorvastatin calcium

Study type

Interventional

Funder types

Industry

Identifiers

NCT02292069

10-VIN-107

Details and patient eligibility

About

This study is to assess the bioequivalence between Amlodipine besylate/Atorvastatin calcium Tablets 10mg/80mg of Dr. Reddy's Laboratories Limited, India and CADUET® (amlodipine besylate and atorvastatin calcium) tablets 10mg/80mg of Pfizer Ireland Pharmaceuticals Dublin, Ireland in healthy, adult,human subjects under Fed conditions.

Full description

Open label, randomized, two-treatment, two-period, two-sequence, oral bioequivalence study of Amlodipine besylate/Atorvastatin calcium Tablets 10mg/80mg under Fed conditions.

Enrollment

90 patients

Sex

All

Ages

18 to 45 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Subjects aged between 18 and 45 years (both inclusive).
Subjects' weight within normal range according to normal values for Body Mass Index (18.5 to 24.9 kg/m2) with minimum of 50 kg weight.
Subjects with normal health as determined by personal medical history, clinical examination and laboratory examinations within the clinically acceptable reference range.
Subjects having normal 12-lead electrocardiogram (ECG).
Subjects having normal chest X-Ray (P/A view) whose X-Ray was taken not more than 6 months prior to the dosing of Period 01.
Subjects having negative urine screen for drugs of abuse (including amphetamines, barbiturates, benzodiazepines, marijuana, cocaine, and morphine).
Subjects having negative alcohol breath test.
Subjects willing to adhere to the protocol requirements and to provide written informed consent.

Exclusion criteria

Hypersensitivity to Amlodipine and Atorvastatin or related class of drugs.
History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological or psychiatric disease or disorder.
Any treatment which could bring about induction or inhibition of hepatic microsomal enzyme system within 1 month of the study starting.
History or presence of significant alcoholism or drug abuse.
History or presence of significant smoking (more than 10 cigarettes or beedi's/day).
History or presence of asthma, urticaria or other significant allergic reactions.
History or presence of significant gastric and/or duodenal ulceration.
History or presence of significant thyroid disease, adrenal dysfunction, organic intracranial lesion such as pituitary tumor.
History or presence of cancer.
Difficulty with donating blood.
Difficulty in swallowing solids like tablets or capsules.
Use of any prescribed or OTC medication during last two weeks prior to dosing in period 01.
Major illness during 3 months before screening.
Participation in a drug research study within past 3 months.
Donation of blood in the past 3 months before screening.
Consumption of grapefruit juice, xanthine-containing products, tobacco containing products or alcohol for within 48 hours prior to dosing.
Positive screening test for any one or more: HIV, Hepatitis B and Hepatitis C.
History or presence of significant easy bruising or bleeding.
History or presence of significant recent trauma.